275 related articles for article (PubMed ID: 23582272)
21. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
[TBL] [Abstract][Full Text] [Related]
22. Discovery of oral and inhaled PDE4 inhibitors.
Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
Huang XF; Cao YJ; Zhen J; Zhang DW; Kong R; Jiang WT; Xu Y; Song GQ; Ke HM; Liu L
Bioorg Med Chem Lett; 2019 Feb; 29(3):481-486. PubMed ID: 30554955
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes.
Mika D; Bobin P; Pomérance M; Lechêne P; Westenbroek RE; Catterall WA; Vandecasteele G; Leroy J; Fischmeister R
Cardiovasc Res; 2013 Nov; 100(2):336-46. PubMed ID: 23933582
[TBL] [Abstract][Full Text] [Related]
25. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
[TBL] [Abstract][Full Text] [Related]
26. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
Stachel SJ; Egbertson MS; Wai J; Machacek M; Toolan DM; Swestock J; Eddins DM; Puri V; McGaughey G; Su HP; Perlow D; Wang D; Ma L; Parthasarathy G; Reid JC; Abeywickrema PD; Smith SM; Uslaner JM
Bioorg Med Chem Lett; 2018 Apr; 28(6):1122-1126. PubMed ID: 29534798
[TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
Tenor H; Hedbom E; Häuselmann HJ; Schudt C; Hatzelmann A
Br J Pharmacol; 2002 Feb; 135(3):609-18. PubMed ID: 11834608
[TBL] [Abstract][Full Text] [Related]
28. Predicting Binding Free Energies of PDE2 Inhibitors. The Difficulties of Protein Conformation.
Pérez-Benito L; Keränen H; van Vlijmen H; Tresadern G
Sci Rep; 2018 Mar; 8(1):4883. PubMed ID: 29559702
[TBL] [Abstract][Full Text] [Related]
29. Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors.
Bhansali SG; Kulkarni VM
SAR QSAR Environ Res; 2014; 25(11):905-37. PubMed ID: 25401514
[TBL] [Abstract][Full Text] [Related]
30. Montmorillonite K-10 catalyzed green synthesis of 2,6-unsubstituted dihydropyridines as potential inhibitors of PDE4.
Reddy TR; Reddy GR; Reddy LS; Meda CL; Parsa KV; Kumar KS; Lingappa Y; Pal M
Eur J Med Chem; 2013 Apr; 62():395-404. PubMed ID: 23380174
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
[TBL] [Abstract][Full Text] [Related]
32. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
[TBL] [Abstract][Full Text] [Related]
33. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
34. Small molecule allosteric modulators of phosphodiesterase 4.
Gurney ME; Burgin AB; Magnusson OT; Stewart LJ
Handb Exp Pharmacol; 2011; (204):167-92. PubMed ID: 21695640
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
Sharma H; Lather V; Grewal AS; Pandita D
Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
[TBL] [Abstract][Full Text] [Related]
36. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Burgin AB; Magnusson OT; Singh J; Witte P; Staker BL; Bjornsson JM; Thorsteinsdottir M; Hrafnsdottir S; Hagen T; Kiselyov AS; Stewart LJ; Gurney ME
Nat Biotechnol; 2010 Jan; 28(1):63-70. PubMed ID: 20037581
[TBL] [Abstract][Full Text] [Related]
37. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E
J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281
[TBL] [Abstract][Full Text] [Related]
38. Pd-mediated functionalization of polysubstituted pyrroles: their evaluation as potential inhibitors of PDE4.
Bhaskar Kumar T; Sumanth Ch; Vaishaly S; Srinivasa Rao M; Chandra Sekhar KB; Meda CL; Kandale A; Rambabu D; Rama Krishna G; Malla Reddy C; Shiva Kumar K; Parsa KV; Pal M
Bioorg Med Chem Lett; 2012 Sep; 22(17):5639-47. PubMed ID: 22871579
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
Day JP; Lindsay B; Riddell T; Jiang Z; Allcock RW; Abraham A; Sookup S; Christian F; Bogum J; Martin EK; Rae RL; Anthony D; Rosair GM; Houslay DM; Huston E; Baillie GS; Klussmann E; Houslay MD; Adams DR
J Med Chem; 2011 May; 54(9):3331-47. PubMed ID: 21456625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
